Test-retest reliability of P50, N100 and P200 auditory sensory gating in healthy subjects

被引:116
作者
Rentzsch, Johannes [1 ]
Jockers-Scheruebl, Maria C. [1 ]
Boutros, Nash N. [2 ]
Gallinat, Juergen [1 ]
机构
[1] Charite Univ Med Berlin, Dept Psychiat, D-14050 Berlin, Germany
[2] Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI USA
关键词
sensory gating; auditory evoked potential; reliability; long-term; p50; n100; p200;
D O I
10.1016/j.ijpsycho.2007.10.006
中图分类号
B84 [心理学];
学科分类号
04 ; 0402 ;
摘要
observed in sequentially occurring P50, N100 and P200 components in a dual-click procedure. Since P50 sensory gating deficits have been observed in schizophrenic patients and first degree relatives, this parameter was suggested as an intermediate phenotype of the disease. However, most studies only show a low reliability for P50 sensory gating and neither N100 nor P200 sensory gating have been sufficiently tested. Methods: Reliability of P50, N100 and P200 sensory gating was measured in 41 healthy subjects in two sessions, four weeks apart, using intra-class correlation. Sensory gating was calculated as ratio-gating (second response magnitude/first response magnitude x 100) as well as difference-gating (first response magnitude minus second response magnitude). Results: The difference-gating showed good to excellent reliabilities independently of the amplitude-measurement method applied (P50 peak-to-peak 0.75 and baseline-to-peak 0.74, N100 peak-to-peak 0.63 and baseline-to-peak 0.70, P200 peak-to-peak 0.82 and baseline-to-peak 0.79). Regarding ratio-gating, best temporal stability was observed for the P200 (peak-to-peak 0.58 and baseline-to-peak 0.62). Reliability of P50 ratio-gating strongly depends on the amplitude-measurement method (peak-to-peak 0.0 and baseline-to-peak 0.46). Conclusion: Regarding long-term reliability in healthy subjects the difference-gating of all three evoked responses and the ratio-gating of the P200 component may be useful tools for clinical or intermediate phenotype studies measuring different stages of the auditory sensory gating process. In contrast, the reliability of the P50 and N100 ratio-gating component seems to be insufficient for this purpose. However, long-term reliability remains to be confirmed in clinical samples. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:81 / 90
页数:10
相关论文
共 85 条
  • [1] NEUROPHYSIOLOGIC STUDIES OF SENSORY GATING IN SCHIZOPHRENIA - COMPARISON OF AUDITORY AND VISUAL RESPONSES
    ADLER, LE
    WALDO, MC
    FREEDMAN, R
    [J]. BIOLOGICAL PSYCHIATRY, 1985, 20 (12) : 1284 - 1296
  • [2] ADLER LE, 1982, BIOL PSYCHIAT, V17, P639
  • [3] LACK OF RELATIONSHIP OF AUDITORY GATING DEFECTS TO NEGATIVE SYMPTOMS IN SCHIZOPHRENIA
    ADLER, LE
    WALDO, MC
    TATCHER, A
    CAWTHRA, E
    BAKER, N
    FREEDMAN, R
    [J]. SCHIZOPHRENIA RESEARCH, 1990, 3 (02) : 131 - 138
  • [4] SENSORY PHYSIOLOGY AND CATECHOLAMINES IN SCHIZOPHRENIA AND MANIA
    ADLER, LE
    GERHARDT, GA
    FRANKS, R
    BAKER, N
    NAGAMOTO, H
    DREBING, C
    FREEDMAN, R
    [J]. PSYCHIATRY RESEARCH, 1990, 31 (03) : 297 - 309
  • [5] Genetic and environmental influences on sensory gating of mid-latency auditory evoked responses: A twin study
    Anokhin, Andrey P.
    Vedeniapin, Andrei B.
    Heath, Andrew C.
    Korzyukov, Oleg
    Boutros, Nashaat N.
    [J]. SCHIZOPHRENIA RESEARCH, 2007, 89 (1-3) : 312 - 319
  • [6] Gating of the vertex somatosensory and auditory evoked potential P50 and the correlation to skin conductance orienting response in healthy men
    Arnfred, SM
    Eder, DN
    Hemmingsen, RP
    Glenthoj, BY
    Chen, ACN
    [J]. PSYCHIATRY RESEARCH, 2001, 101 (03) : 221 - 235
  • [7] NEUROPHYSIOLOGICAL ASSESSMENT OF SENSORY GATING IN PSYCHIATRIC-INPATIENTS - COMPARISON BETWEEN SCHIZOPHRENIA AND OTHER DIAGNOSES
    BAKER, N
    ADLER, LE
    FRANKS, RD
    WALDO, M
    BERRY, S
    NAGAMOTO, H
    MUCKLE, A
    FREEDMAN, R
    [J]. BIOLOGICAL PSYCHIATRY, 1987, 22 (05) : 603 - 617
  • [8] SENSORY GATING DEFICITS IN PSYCHIATRIC-INPATIENTS - RELATION TO CATECHOLAMINE METABOLITES IN DIFFERENT DIAGNOSTIC GROUPS
    BAKER, NJ
    STAUNTON, M
    ADLER, LE
    GERHARDT, GA
    DREBING, C
    WALDO, M
    NAGAMOTO, H
    FREEDMAN, R
    [J]. BIOLOGICAL PSYCHIATRY, 1990, 27 (05) : 519 - 528
  • [9] Endophenotypes for psychiatric disorders: ready for primetime?
    Bearden, Carrie E.
    Freimer, Nelson B.
    [J]. TRENDS IN GENETICS, 2006, 22 (06) : 306 - 313
  • [10] Clozapine, but not typical antipsychotics, correct P50 suppression deficit in patients with schizophrenia
    Becker, J
    Gomes, I
    Ghisolfi, ES
    Schuch, A
    Ramos, FLP
    Ehlers, JA
    Nora, DB
    Lara, DR
    da Costa, JC
    [J]. CLINICAL NEUROPHYSIOLOGY, 2004, 115 (02) : 396 - 401